Heron Therapeutics (HRTX) Other Non-Current Liabilities (2022 - 2026)
Heron Therapeutics (HRTX) reported Other Non-Current Liabilities of $4.9 million for Q1 2026, up 622.73% on a YoY basis from $682000.0 in Q1 2025, and up 2.52% quarter-over-quarter from $4.8 million in Q4 2025.
Heron Therapeutics (HRTX) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
Heron Therapeutics has reported Other Non-Current Liabilities for 5 years, with the latest figure at $4.9 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 622.73% year-over-year to $4.9 million; the trailing twelve-month figure through Mar 2026 stood at $4.9 million (up 622.73% YoY), and the FY2025 full-year result was $4.8 million, up 681.79% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $4.9 million, up from $4.8 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $4.9 million in Q1 2026, with the low at $241000.0 in Q1 2022.
- Historically, Other Non-Current Liabilities has averaged $1.1 million across 5 years, with a median of $241000.0 in 2022.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities changed 0.0% — and 2025, when it surged 1847.72%.
- Heron Therapeutics' Other Non-Current Liabilities stood at $241000.0 in 2022, then changed by 0.0% to $241000.0 in 2023, then jumped by 155.19% to $615000.0 in 2024, then jumped by 681.79% to $4.8 million in 2025, then rose by 2.52% to $4.9 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $4.9 million (Q1 2026), $4.8 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Heron Therapeutics | 85.57 Mn | 55.60 Mn | 24.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.93 Mn |
| Dec 31, 2025 | 4.81 Mn |
| Sep 30, 2025 | 4.69 Mn |
| Jun 30, 2025 | 747,000.00 |
| Mar 31, 2025 | 682,000.00 |
| Dec 31, 2024 | 615,000.00 |
| Sep 30, 2024 | 241,000.00 |
| Jun 30, 2024 | 241,000.00 |
| Mar 31, 2024 | 241,000.00 |
| Dec 31, 2023 | 241,000.00 |
| Sep 30, 2023 | 241,000.00 |
| Jun 30, 2023 | 241,000.00 |
| Mar 31, 2023 | 241,000.00 |
| Dec 31, 2022 | 241,000.00 |
| Sep 30, 2022 | 241,000.00 |
| Jun 30, 2022 | 241,000.00 |
| Mar 31, 2022 | 241,000.00 |